Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial

Russo, 2007, History of cannabis and its preparations in saga, science, and sobriquet, Chem Biodivers, 4, 1614, 10.1002/cbdv.200790144

Gowers, 1881

Gross, 2004, Marijuana use and epilepsy: prevalence in patients of a tertiary care epilepsy center, Neurology, 62, 2095, 10.1212/01.WNL.0000127623.03766.75

Mortati, 2007, Marijuana: an effective antiepileptic treatment in partial epilepsy? A case report and review of the literature, Rev Neurol Dis, 4, 103

Hill, 2013, The development of cannabinoid based therapies for epilepsy, 164

Volkow, 2014, Adverse health effects of marijuana use, N Eng J Med, 370, 2219, 10.1056/NEJMra1402309

Porter, 2013, Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy, Epilepsy Behav, 29, 574, 10.1016/j.yebeh.2013.08.037

Gupta

Maa, 2014, The case for medical marijuana in epilepsy, Epilepsia, 55, 783, 10.1111/epi.12610

Devinsky, 2014, Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders, Epilepsia, 55, 791, 10.1111/epi.12631

Gloss, 2014, Cannabinoids for epilepsy, Cochrane Database Syst Rev, 3, 10.1002/14651858.CD009270.pub3

Koppel, 2014, Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology, Neurology, 82, 1556, 10.1212/WNL.0000000000000363

Wade, 2006, Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis, Mult Scler, 12, 639, 10.1177/1352458505070618

Panelli, 2007, The Liverpool Adverse Events Profile: relation to AED use and mood, Epilepsia, 48, 456, 10.1111/j.1528-1167.2006.00956.x

Morita, 2012, Development and validation of the pediatric epilepsy side effects questionnaire, Neurology, 79, 1252, 10.1212/WNL.0b013e3182635b87

Bornheim, 1993, Characterization of cannabidiol-mediated cytochrome P450 inactivation, Biochem Pharmacol, 45, 1323, 10.1016/0006-2952(93)90286-6

Friedman, 2014

Geffrey, 2015, Drug–drug interaction between clobazam and cannabidiol in children with refractory epilepsy, Epilepsia, 56, 1246, 10.1111/epi.13060

Esposito, 2013, Cannabidiol in inflammatory bowel diseases: a brief overview, Phytother Res, 27, 633, 10.1002/ptr.4781

Parmeggiani, 2004, Unusual side-effects due to clobazam: a case report with genetic study of CYP2C19, Brain Dev, 26, 63, 10.1016/S0387-7604(03)00074-3

Yamamoto, 2013, Influence of CYP2C19 polymorphism and concomitant antiepileptic drugs on serum clobazam and N-desmethyl clobazam concentrations in patients with epilepsy, Ther Drug Monit, 35, 305, 10.1097/FTD.0b013e318283b49a

Zaccara, 2015, Placebo and nocebo responses in drug trials of epilepsy, Epilepsy Behav, 43, 128, 10.1016/j.yebeh.2014.12.004

Purcarin, 2014, Experience in the use of clobazam in the treatment of Lennox-Gastaut syndrome, Ther Adv Neurol Disord, 7, 169, 10.1177/1756285614521314

Press, 2015, Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy, Epilepsy Behav, 45, 49, 10.1016/j.yebeh.2015.02.043

Mink, 2013, Classification and natural history of the neuronal ceroid lipofuscinoses, J Child Neurol, 28, 1101, 10.1177/0883073813494268